🔥🐔 BizChicken 🐔🔥

Companies Similar to Abivax SA American Depositary Shares

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Biogen Inc.

Biogen Inc. logo
Market Cap: Highest
Employees: Highest

TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, FAMPYRA, SPINRAZA, FUMADERM, BENEPALI, ADUHELM, IMRALDI, FLIXABI, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS

Biogen Inc. focuses on discovering, developing, manufacturing, and delivering therapies for neurological and neurodegenerative diseases, including multiple sclerosis, spinal muscular atrophy, plaque psoriasis, Alzheimer's disease, and various cancers and autoimmune conditions.

Tags: biotechnology, multiple sclerosis, neurodegenerative diseases, neurological diseases, pharmaceuticals

Symbol: BIIB

Recent Price: $150.19

Industry: Drug Manufacturers - General

CEO: Mr. Christopher A. Viehbacher

Sector: Healthcare

Employees: 7570

Address: 225 Binney Street, Cambridge, MA 02142

Phone: 617 679 2000

Leadership

  • Christopher A. Viehbacher, President and Chief Executive Officer
  • Susan H. Alexander, Chief Legal Officer
  • Ginger Gregory, Ph.D., Chief Human Resources Officer
  • Jane Grogan, Ph.D., Head of Research
  • Rachid Izzar, Head of Global Product Strategy & Commercialization
  • Adam Keeney, Head of Corporate Development
  • Michael McDonnell, Chief Financial Officer
  • Nicole Murphy, Head of Pharmaceutical Operations and Technology
  • Priya Singhal, M.D., M.P.H., Head of Development and Interim Chief Medical Officer
  • Alisha Alaimo, President, Head of North America
  • Stephen Amato, Head of Investor Relations
  • Natacha Gassenbach, Head of Corporate Affairs, Chief Communications Officer
  • Fraser Hall, President, Head of Intercontinental Region
  • Wolfram Schmidt, President, Head of Europe
  • Kendra Thomas, Head of Global Workforce Diversity, Equity & Inclusion (DE&I)
  • Caroline Dorsa, Chair of the Board
  • Maria C. Freire, Ph.D., Director
  • William A. Hawkins, Director
  • Susan Langer, Director
  • Jesus B. Mantas, Director
  • Lloyd B. Minor, M.D., Director
  • Monish Patolawala, Director
  • Eric K. Rowinsky, M.D., Director
  • Stephen A. Sherwin, M.D., Director

Last updated: 2024-12-31

AnaptysBio, Inc.

AnaptysBio, Inc. logo
Market Cap: Medium
Employees: Low

Imsidolimab, Rosnilimab, ANB032

Anaptys Bio, Inc. is a clinical stage biotechnology company focused on developing therapeutic product candidates for inflammation and immuno-oncology indications. Their products target dermatological inflammatory diseases and other human inflammatory conditions.

Tags: antibody development, biotechnology, immuno-oncology, inflammation, therapeutics

Symbol: ANAB

Recent Price: $13.22

Industry: Biotechnology

CEO: Mr. Daniel R. Faga

Sector: Healthcare

Employees: 117

Address: 10770 Wateridge Circle, San Diego, CA 92121-5801

Phone: 858 362 6295

Last updated: 2024-12-31

Vaccinex, Inc.

Vaccinex, Inc. logo
Market Cap: Lowest
Employees: Lowest

pepinemab

Vaccinex, Inc., a clinical-stage biotechnology company, focuses on developing targeted biotherapeutics for cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate, pepinemab, is in clinical trials for multiple serious conditions.

Tags: autoimmune disorders, biotechnology, biotherapeutics, cancer, clinical trials, neurodegenerative diseases

Symbol: VCNX

Recent Price: $1.11

Industry: Biotechnology

CEO: Dr. Maurice Zauderer Ph.D.

Sector: Healthcare

Employees: 37

Address: 1895 Mount Hope Avenue, Rochester, NY 14620

Phone: 585 271 2700

Last updated: 2024-12-31

Absci Corporation

Absci Corporation logo
Market Cap: Medium
Employees: Low

Integrated Drug Creation Platform

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using an integrated drug creation platform for partners in the United States. Its platform enables the creation of biologics by unifying the drug discovery and cell line development processes.

Tags: AI, biologics, cell line development, drug discovery, pharmaceuticals

Symbol: ABSI

Recent Price: $2.65

Industry: Biotechnology

CEO: Mr. Sean McClain

Sector: Healthcare

Employees: 155

Address: 18105 SE Mill Plain Boulevard, Vancouver, WA 98683

Phone: 360 949 1041

Last updated: 2024-12-31

Abivax SA American Depositary Shares

Abivax SA American Depositary Shares logo
Market Cap: Medium
Employees: Lowest

obefazimod

ABIVAX Société Anonyme is a clinical-stage biotechnology company developing therapeutics to modulate the immune response for chronic inflammatory diseases. Their lead drug candidate, obefazimod, is in Phase 3 clinical trials for ulcerative colitis.

Tags: biotechnology, chronic inflammatory diseases, clinical trials, immune response, ulcerative colitis

Symbol: ABVX

Recent Price: $7.05

Industry: Biotechnology

CEO: Mr. Marc M. P. de Garidel M.B.A.

Sector: Healthcare

Employees: 62

Address: 7-11 boulevard Haussmann, Paris, null 75009

Phone: 33 1 53 83 09 63

Leadership

  • Marc de Garidel, MBA, Chief Executive Officer
  • Didier Blondel, EVP, Chief Financial Officer & Board Secretary
  • Fabio Cataldi, MD, Chief Medical Officer
  • Ida Hatoum, Chief People Officer, Chief Compliance Officer
  • David Zhang, PhD, Chief Strategy Officer
  • Pierre Courteille, Pharmacist, MBA, Chief Business Officer
  • Didier Scherrer, PhD, Chief Scientific Officer
  • Jérôme Denis, PhD, EVP, Process Development & Manufacturing
  • Nadège Briancon-Eris, PhD, Senior Vice President, Global Head of Program Management
  • Sylvie Grégoire, PharmD, Chair of the Board
  • Corinna zur Bonsen-Thomas, Co-founder and CEO of RetInSight; Former General Counsel at Baxter/Baxalta International
  • Philippe Pouletty, MD, Founder of Abivax; Managing Partner of Truffle Capital
  • June Lee, MD FACCP, Venture Partner at 5AM Ventures
  • Kinam Hong, MD, MBA, CFA, Partner at the Crossover Fund Sofinnova
  • Troy Ignelzi, CFO of Rapport Therapeutics
  • Camilla Soenderby, Board Member of BB Biotech, F2G, and Affibody; Member of Novo Holdings Advisory Group; Industrial Advisor for EQT
  • Mary Mantock, Senior Vice President, Global Head of Regulatory Affairs
  • Hema Keshava, Senior Vice President, Finance
  • Cristina Damatarca, MD, PgD, Senior Vice President, Global Head of Drug Safety and Pharmacovigilance
  • Patrick Malloy, Senior Vice President, Investor Relations
  • Douglas Jacobstein, MD, Senior Vice President, Global Head of Clinical Development
  • Jennifer Fine, ScD, Senior Vice President, Global Head of HEOR and RWE
  • Kevin Shan, PhD, Vice President, Global Head of Biometrics
  • Chris Rabbat, PhD, Vice President, Global Head of Medical Affairs
  • Ana Sharma, MPH, Vice President, Global Head of Quality
  • Sophie LaCourrege, Vice President, HR Business Partner, Engagement and Culture

Last updated: 2024-12-31

Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

Ibezapolstat

Acurx Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing antibiotics for bacterial infections, with their lead candidate Ibezapolstat targeting Clostridium difficile infections.

Tags: antibiotics, bacterial infections, biopharmaceutical, clinical stage, ibezapolstat

Symbol: ACXP

Recent Price: $0.85

Industry: Biotechnology

CEO: Mr. David P. Luci CPA, Esq., J.D.

Sector: Healthcare

Employees: 4

Address: 259 Liberty Avenue, Staten Island, NY 10305

Phone: 917-533-1469

Last updated: 2024-12-31

ADMA Biologics, Inc.

ADMA Biologics, Inc. logo
Market Cap: High
Employees: Medium

BIVIGAM, ASCENIV, Nabi-HB

ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing specialty plasma-derived biologics for treating immune deficiencies and infectious diseases.

Tags: biologics, biopharmaceutical, immunodeficiency, infectious diseases, plasma-derived

Symbol: ADMA

Recent Price: $17.49

Industry: Biotechnology

CEO: Mr. Adam S. Grossman

Sector: Healthcare

Employees: 624

Address: 465 State Route 17, Ramsey, NJ 07446

Phone: 201 478 5552

Leadership

  • Adam S. Grossman, Founder, Director, President, & Chief Executive Officer
  • Kaitlin Kestenberg, Chief Operating Officer & Senior Vice President of Compliance
  • Brad Tade, Chief Financial Officer & Treasurer
  • Doug Chambers, Vice President, Quality
  • Daniel Garcia, Vice President, IgG Product Management
  • Jeffrey Janek, Vice President, Production Operations
  • Michael Least, Vice President, Market Access & National Accounts
  • Drew Pantello, Vice President, Marketing & Corporate Development
  • Cindy Petersen, Vice President, Human Resources
  • Michael Space, Vice President, Long Range Planning & Analysis
  • Shane Stremming, Vice President, Operations for ADMA BioCenters
  • Jeffrey Gruenglas, Executive Director, Government Affairs, Health Policy & Scientific Communications
  • John Hafl, Executive Director, Sales
  • Sheri Klostermeyer, Executive Director, Supply Chain
  • Steven A. Elms, Chairman
  • Jerrold B. Grossman, D.P.S., Founder & Vice Chairman
  • Alison C. Finger, Director
  • Bryant E. Fong, Director
  • Lawrence P. Guiheen, Director
  • Young T. Kwon, PhD, Director

Last updated: 2024-12-31

Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc. logo
Market Cap: Low
Employees: Low

Vadadustat

Akebia Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutics for kidney disease patients, with a lead product vadadustat for treating anemia due to chronic kidney disease.

Tags: CKD, anemia, biopharmaceutical, chronic kidney disease, kidney diseases, therapeutics, vadadustat

Symbol: AKBA

Recent Price: $1.85

Industry: Biotechnology

CEO: Mr. John P. Butler MBA

Sector: Healthcare

Employees: 167

Address: 245 First Street, Cambridge, MA 02142

Phone: 617 871 2098

Last updated: 2024-12-31

Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc. logo
Market Cap: High
Employees: Medium

AXS-05, AXS-07, AXS-12, AXS-14

Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapies for central nervous system disorders such as major depressive disorder, migraine, narcolepsy, and fibromyalgia.

Tags: CNS disorders, biopharmaceutical, clinical trials, depression, fibromyalgia, migraine, narcolepsy

Symbol: AXSM

Recent Price: $84.78

Industry: Biotechnology

CEO: Dr. Herriot Tabuteau M.D.

Sector: Healthcare

Employees: 589

Address: 22 Cortlandt Street, New York, NY 10007

Phone: 212 332 3241

Leadership

  • Herriot Tabuteau, MD, CHIEF EXECUTIVE OFFICER
  • Nick Pizzie, CPA, MBA, CHIEF FINANCIAL OFFICER
  • Mark Jacobson, MA, CHIEF OPERATING OFFICER
  • Hunter Murdock, Esq., GENERAL COUNSEL
  • ari Maizel, Executive Vice President, Head of Commercial
  • Mark Coleman, MD, DIRECTOR
  • Roger Jeffs, PhD, DIRECTOR
  • Susan Mahony, PhD, MBA, DIRECTOR
  • Mark Saad, DIRECTOR

Last updated: 2024-12-31

BeiGene, Ltd.

BeiGene, Ltd. logo
Market Cap: Highest
Employees: Highest

BRUKINSA, Tislelizumab, REVLIMID, VIDAZA, XGEVA, BLINCYTO, KYPROLIS, SYLVANT, QARZIBA, Pamiparib, Pobevcy

Bei Gene, Ltd. is a biotechnology company focused on discovering, developing, manufacturing, and commercializing a wide range of medicines globally, specializing in oncology treatments and clinical stage drug candidates.

Tags: Biotechnology, Medicines, Oncology, Pharmaceuticals, Research and Development

Symbol: BGNE

Recent Price: $183.81

Industry: Biotechnology

CEO: Mr. John V. Oyler

Sector: Healthcare

Employees: 10000

Address: 55 Cambridge Parkway, Cambridge, MA 02142

Phone: 781-801-1800

Leadership

  • John V. Oyler, Co-Founder, Chairman and CEO
  • Xiaodong Wang, Ph.D., Co-Founder, Chairman of Scientific Advisory Board
  • Olivier Brandicourt, M.D., Director
  • Margaret Dugan, M.D., Director
  • Donald W. Glazer, Director
  • Michael Goller, Director
  • Anthony Hooper, Director
  • Ranjeev Krishana, Director
  • Michael Nuoqing Yi, Director
  • Alessandro Riva, M.D., Director
  • Corsee Sanders, Ph.D., Director
  • Shalini Sharp, Director
  • Steven Young, Ph.D., Acting Head of Medicinal Chemistry
  • Ron Levy, M.D., Scientific Advisory Board
  • Neal Rosen, M.D., Ph.D., Scientific Advisory Board
  • Charles Sawyers, M.D., Scientific Advisory Board
  • David Schenkein, M.D., Scientific Advisory Board
  • Melika Davis, SVP & Global Head, Clinical Operations
  • Clare Fisher, SVP, Business Development, Licensing, and M&A (ex-China)
  • Tony Guo, Ph.D., SVP, Global Statistics & Data Science
  • Dany Habr, M.D., Head of Medical Affairs, North America & International Markets
  • Graham Hardiman, Global Head of HR
  • Shreya Devendra Jani, SVP, Corporate Affairs
  • Jaspreet Jaggi, M.D., Ph.D., SVP and Head, Clinical Portfolio Strategy
  • Yang Ji, Chief Compliance Officer
  • Mark Lanasa, M.D., Ph.D., SVP, Chief Medical Officer, Solid Tumors
  • Chan Lee, General Counsel
  • Kyu-Sung Lee, Ph.D., SVP, Global Head of Technical Operations and Manufacturing
  • Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer
  • Kyoung Lim, VP of Supply Chain
  • Han Ma, M.D., Ph.D., Chief Safety Officer and SVP, Global Patient Safety
  • Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology
  • Richard O’Keeffe, Head of Global Quality
  • Jurij Petrin, M.D., Head of New Market Development
  • Yan Qi, Ph.D., SVP, Head of Public Affairs
  • Hongyu Qian, SVP, Medical Affairs
  • Jason Radford, SVP, Strategy & Corporate Development
  • Anand Reddi, VP, Global Strategic Initiatives and Corporate Operations, Chief of Staff to the CEO
  • Adam Roach, VP and Head of Asia Pacific
  • Aaron Rosenberg, Chief Financial Officer
  • Michael Schoen, Strategic Advisor and Special Assistant to the CEO
  • Matt Shaulis, General Manager of North America
  • Lai Wang, Ph.D., Global Head of R&D
  • Zhiwei Wang, Ph.D., SVP, Research Head of Chemistry
  • Beth Wensley, SVP, Head of Portfolio and Program Management
  • Kimberly Wolf, SVP, Global Commercial Strategy & Operations
  • Xiaobin Wu, Ph.D., President, Chief Operating Officer
  • Eva Yin, Chief Commercial Officer, Greater China

Last updated: 2024-12-31

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. logo
Market Cap: Highest
Employees: High

Vimizim

Bio Marin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Their products cater to conditions like mucopolysaccharidosis, phenylketonuria, Batten disease, and more.

Tags: biotechnology, enzyme replacement therapy, healthcare, pharmaceutical, rare diseases

Symbol: BMRN

Recent Price: $65.45

Industry: Biotechnology

CEO: Mr. Alexander Hardy

Sector: Healthcare

Employees: 3401

Address: 770 Lindaro Street, San Rafael, CA 94901

Phone: 415 506 6700

Leadership

  • Mark Enyedy,
  • Alexander Hardy,
  • Elaine J. Heron,
  • G. Eric Davis, Executive Vice President, Chief Legal Officer
  • Greg Friberg, Executive Vice President, Chief Research & Development Officer
  • C. Greg Guyer, Executive Vice President, Chief Technical Officer
  • Cristin Hubbard, Executive Vice President, Chief Commercial Officer
  • Marni Kottle, Executive Vice President, Chief Corporate Affairs Officer
  • Brian R. Mueller, Executive Vice President, Chief Financial Officer
  • James Sabry, Executive Vice President, Chief Business Officer
  • Amy Wireman, Executive Vice President, Chief People Officer
  • Richard A. Meier,
  • Elizabeth McKee Anderson,
  • Barbara Bodem,
  • Athena Countouriotis,
  • Willard H. Dere,
  • Maykin Ho,
  • Robert J. Hombach,
  • David E.I. Pyott,

Last updated: 2024-12-31

Curis, Inc.

Curis, Inc. logo
Market Cap: Lowest
Employees: Lowest

Emavusertib

Curis, Inc. is a biotechnology company focused on discovering and developing drug candidates for treating human cancers, with a range of clinical stage and pipeline products targeting lymphomas, leukemia, and solid tumors.

Tags: biotechnology, cancer treatment, clinical trials, drug development, oncology

Symbol: CRIS

Recent Price: $3.14

Industry: Biotechnology

CEO: Mr. James E. Dentzer

Sector: Healthcare

Employees: 49

Address: Building C, Lexington, MA 02421

Phone: 617 503 6500

Leadership

  • Martyn D. Greenacre, Chair of the Board
  • John Hohneker, M.D., Director
  • Kenneth I. Kaitin, Ph.D., Director
  • Anne E. Borgman, M.D., Director
  • Marc Rubin, M.D., Director
  • James Dentzer, Chief Executive Officer and Director

Last updated: 2024-12-31

Immunovant, Inc.

Immunovant, Inc. logo
Market Cap: High
Employees: Low

batoclimab

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases, including batoclimab for myasthenia gravis and thyroid eye disease.

Tags: autoimmune diseases, biopharmaceutical, clinical trials, monoclonal antibodies

Symbol: IMVT

Recent Price: $23.88

Industry: Biotechnology

CEO: Dr. Peter Salzmann M.B.A., M.D.

Sector: Healthcare

Employees: 207

Address: 320 West 37th Street, New York, NY 10018

Phone: 917 580 3099

Leadership

  • Pete Salzmann, M.D., MBA, Chief Executive Officer
  • Renee Barnett, MBA, Chief Financial Officer
  • Christine Blodgett, Senior Vice President of Human Resources
  • Andy Deig, Senior Vice President Strategic Finance
  • Michael Geffner M.D., MBA, Chief Medical Officer
  • Julie Kirschling, Senior Vice President, Program and Alliance Management
  • Mark Levine, Chief Legal Officer and Corporate Secretary
  • Bill Macias, M.D., Ph.D., Chief Medical Officer
  • Becky Merlina, Senior Vice President, Global Head of Quality
  • Jody Roth, MS, RAC, PMP, Senior Vice President, Regulatory Affairs
  • Jay S. Stout, PhD, Chief Technology Officer
  • Yan Zheng, Ph.D., Senior Vice President Biostatistics, Programming & Data Management
  • Chandra Adams, Vice President, Associate General Counsel
  • Maria Alba, M.D., Vice President of Clinical Development
  • Farah Ali, Vice President, Clinical Development
  • Jennifer Ashley, Vice President, Associate General Counsel
  • Annetta Beauregard, Vice President, Regulatory Affairs Strategy
  • Harry Berlanga, MSc., VP, CMC & Distribution Quality
  • Ranjit Deshmukh, Ph.D., Vice President of CMC and Technical Operations
  • Scott Forman, MBA, Vice President, Program Management
  • Tom Forman, MBA, Vice President, CMC Project Management
  • Ian Gourley, M.D., Vice President of Clinical Development
  • Thomas Hardy, M.D., Ph.D., Vice President of Drug Safety and Pharmacovigilance
  • Laci Hasenour, Vice President Marketing, Neurology
  • Aileen Ilaria, MBA, Vice President, Clinical Operations – Global Site Management
  • Claudia Jacobs, Ph.D., Vice President of CMC Project Management Operations and Clinical Supply
  • Jonathan Janes, MB, Vice President Clinical Development
  • Ant Kidwell, Vice President of IT and Facilities
  • Chedvi Levin-Sister, Vice President of Finance
  • Launi Masterson, Vice President of Clinical Operations
  • Andy Minke, Vice President Program Management
  • Linda McKerral, Vice President, CMC Analytical Sciences
  • Pooja Mehta, Vice President Drug Substance Tech Transfer
  • Regina Mirra, VP, Regulatory Operational Excellence
  • Jennifer Moseley, Vice President of Clinical Operations
  • Sheetal Patel M.D., MS MBA, Vice President of Clinical Development
  • Cassandra Pauyo, Vice President, Data Management
  • Rod Saponjic Ph.D., MBA, Vice President of Clinical Operations
  • Lauren Schrier, MBA, Vice President of Marketing
  • Frank Torti, M.D., Chairperson of Board of Directors
  • Andrew Fromkin, Member of Board of Directors
  • Douglas Hughes, Member of Board of Directors
  • George Migausky, Member of Board of Directors
  • Atul Pande, M.D., Member of Board of Directors
  • Eric Venker, M.D., Pharm.D., Member of Board of Directors

Last updated: 2024-12-31

MediciNova, Inc.

MediciNova, Inc. logo
Market Cap: Low
Employees: Lowest

MN-166 (ibudilast)

Medici Nova, Inc. is a biopharmaceutical company focused on developing novel therapeutics for serious diseases with unmet medical needs, including neurologic disorders, fibrotic diseases, and solid tumor cancers.

Tags: United States, biopharmaceutical, fibrotic diseases, neurological disorders, novel therapeutics, solid tumors, unmet medical needs

Symbol: MNOV

Recent Price: $2.11

Industry: Biotechnology

CEO: Dr. Yuichi Iwaki M.D., Ph.D.

Sector: Healthcare

Employees: 13

Address: 4275 Executive Square, La Jolla, CA 92037

Phone: 858 373 1500

Leadership

  • Yuichi Iwaki, M.D., Ph.D., President and Chief Executive Officer, and Founder
  • Kazuko Matsuda, M.D., Ph.D, MPH, Chief Medical Officer
  • David H. Crean, Ph.D., Chief Business Officer
  • Jason J. Kruger, CPA (inactive), Chief Financial Officer
  • Hideki Nagao, Member of the Board of Directors
  • Carolyn Beaver, Member of the Board of Directors
  • Nicole Lemerond, CFA, Member of the Board of Directors

Last updated: 2024-12-31

Ovid Therapeutics Inc.

Ovid Therapeutics Inc. logo
Market Cap: Low
Employees: Lowest

OV101, OV329, OV350, OV882, OV815

Ovid Therapeutics Inc., a biopharmaceutical company based in New York, is dedicated to developing impactful medicines for neurological disorders. They have a range of drug candidates like OV101 and are involved in various clinical trials.

Tags: biopharmaceutical, clinical trials, medicine development, neurological disorders

Symbol: OVID

Recent Price: $0.96

Industry: Biotechnology

CEO: Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D.

Sector: Healthcare

Employees: 40

Address: 1460 Broadway, New York, NY 10036

Phone: 646 661 7661

Leadership

  • Jeremy M. Levin, D.Phil, MB BChir, Chief Executive Officer and Chairman
  • Meg Alexander, President and Chief Operating Officer
  • Zhong Zhong, Ph.D., Chief Scientific Officer
  • Jeffrey Rona, Chief Business and Financial Officer
  • Amanda Banks, M.D., Chief Development Officer
  • Julia Tsai, Ph.D., Senior Vice President of Clinical Development
  • Karen Bernstein, Ph.D., Director, Chair of the Compensation Committee, Member of the Audit and Nominating and Corporate Governance Committees
  • Barbara G. Duncan, MBA, Director, Chair of the Audit Committee, Member of the Nominating and Corporate Governance Committee
  • Bart Friedman, J.D., Lead Independent Director, Chair of the Nominating and Corporate Governance Committee, Member of the Audit and Compensation Committees
  • Michael Poole, M.D., FACP, Director, Member of the Audit and Compensation Committees
  • Kevin Fitzgerald, Ph.D., Director, Member of the Nominating and Corporate Governance Committee

Last updated: 2024-12-31

Cassava Sciences, Inc.

Cassava Sciences, Inc. logo
Market Cap: High
Employees: Lowest

simufilam

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead product candidate, simufilam, is a small molecule drug, recently completed Phase 2b clinical trial. The company also develops Sava Dx, a diagnostic to detect Alzheimer's disease.

Tags: Alzheimer's, Sava Dx, biotechnology, drug development, neurodegenerative diseases, simufilam

Symbol: SAVA

Recent Price: $2.40

Industry: Biotechnology

CEO: Mr. Richard Jon Barry

Sector: Healthcare

Employees: 29

Address: 7801 North Capital of Texas Highway, Austin, TX 78731

Phone: 512 501 2444

Last updated: 2024-12-31

AbbVie Inc.

AbbVie Inc. logo
Market Cap: Highest
Employees: Highest

HUMIRA, SKYRIZI, RINVOQ, IMBRUVICA, VENCLEXTA, MAVYRET, CREON, Synthroid, Linzess/Constella, Lupron

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide, offering a range of therapies including HUMIRA for autoimmune diseases and MAVYRET for HCV infection.

Tags: autoimmune diseases, biotechnology, gastroenterology, healthcare, oncology, pharmaceuticals

Symbol: ABBV

Recent Price: $176.20

Industry: Drug Manufacturers - General

CEO: Mr. Robert A. Michael

Sector: Healthcare

Employees: 50000

Address: 1 North Waukegan Road, North Chicago, IL 60064-6400

Phone: 847 932 7900

Last updated: 2024-12-31

Abeona Therapeutics Inc.

Abeona Therapeutics Inc. logo
Market Cap: Low
Employees: Low

EB-101

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa.

Tags: EB-101, biopharmaceutical, cell therapy, clinical trials, gene therapy, rare genetic diseases

Symbol: ABEO

Recent Price: $5.61

Industry: Biotechnology

CEO: Dr. Vishwas Seshadri M.B.A., Ph.D.

Sector: Healthcare

Employees: 84

Address: 1330 Avenue of the Americas, New York, NY 10019

Phone: 646 813 4701

Last updated: 2024-12-31

SCYNEXIS, Inc.

SCYNEXIS, Inc. logo
Market Cap: Lowest
Employees: Lowest

BREXAFEMME (ibrexafungerp tablets)

SCYNEXIS, Inc. is a biotechnology company focused on developing products for the treatment of fungal infections. They offer BREXAFEMME for the treatment of vulvovaginal candidiasis and are developing Ibrexafungerp, an oral and intravenous drug for various fungal infections.

Tags: BREXAFEMME, Biotechnology, Fungal Infections, Ibrexafungerp, Pharmaceuticals

Symbol: SCYX

Recent Price: $1.07

Industry: Drug Manufacturers - Specialty & Generic

CEO: Dr. David Gonzalez Angulo M.D.

Sector: Healthcare

Employees: 29

Address: 1 Evertrust Plaza, Jersey City, NJ 07302-6548

Phone: 201 884 5485

Leadership

  • Armando Anido, Director
  • Steven C. Gilman, Ph.D., Director
  • David Angulo, M.D., President and Chief Executive Officer
  • Scott Sukenick, Chief Legal Officer
  • Ivor Macleod, MBA, CPA, Chief Financial Officer
  • Daniella Gigante, Vice President, Human Resources and Information Technology
  • Rossana Ferrara-Pontoriero, Ph.D., Vice President, Business Development and Alliance Management
  • Guy Macdonald, Chairman of the Board
  • Ann F. Hanham, Ph.D., Director
  • David Hastings, Director
  • Philippe Tinmouth, Director

Last updated: 2024-12-31

Ventyx Biosciences, Inc.

Ventyx Biosciences, Inc. logo
Market Cap: Low
Employees: Low

VTX958

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule product candidates for the treatment of inflammatory diseases and autoimmune disorders. Key products include VTX958 for immune-mediated diseases, VTX002 for ulcerative colitis, and VTX2735 for systemic inflammatory diseases.

Tags: VTX002, VTX2735, VTX958, autoimmune disorders, biopharmaceutical, clinical trials, inflammatory diseases, small molecule

Symbol: VTYX

Recent Price: $2.23

Industry: Biotechnology

CEO: Dr. Raju S. Mohan Ph.D.

Sector: Healthcare

Employees: 73

Address: 662 Encinitas Boulevard, Encinitas, CA 92024

Phone: 760 593 4832

Last updated: 2024-12-31